US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
US FDA approves Amgen drug for small cell lung cancer
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
FDA approves Amgen drug for tough-to-treat form of lung cancer
Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.
Should you buy Amgen’s stock above $300?
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
healthandpharma14d
FDA Approves IMDELLTRA for Lung Cancer After Demonstrating a 40% Response Rate
The FDA has granted accelerated approval to IMDELLTRA™ for treating extensive-stage small cell lung cancer following platinum ...
FDA approves new drug for deadly lung cancer
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung ...
US FDA approves two biosimilars for blockbuster eye drug Eylea
The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its ...
FDA Approves First Interchangeable Biosimilar for Two Rare Diseases
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
West Hawaii Today11d
FDA approves drug for persistently deadly form of lung cancer
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...
Le Lézard15d
FDA APPROVES IMDELLTRAtm (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
THOUSAND OAKS, Calif., May 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRAtm (tarlatamab-dlle) for the treatment of ...
Pharmaceutical Technology2d
Verona prepares for anticipated US launch of ensifentrine for COPD in Q3 2024
Ensifentrine is a first-in-class dual phosphodiesterase 3/4 inhibitor to treat chronic obstructive pulmonary disease (COPD).
oncnursingnews14d
FDA Approves Tarlatamab for Extensive-Stage SCLC
Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.